Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a42946731d0a224d

Jump to content

Galvani Bioelectronics

From Wikipedia, the free encyclopedia

Galvani Bioelectronics
TypeSubsidiary
IndustryBioelectronics
FoundedNovember 2016[1]
Founders[2]
Headquarters,
Key peopleKristoffer Famm (President)[4]
ParentGlaxoSmithKline (55% equity interest)[3]
Websitegalvani.bio

Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.

History

[edit]

It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]

Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.

In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]

References

[edit]
  1. 1 2 3 "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
  2. 1 2 "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
  3. 1 2 3 4 5 Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
  4. ↑ "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
  5. ↑ Kollewe, Julia (28 August 2017). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 3 August 2018.
  6. ↑ "Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future". Worldanalytics24.com. 23 January 2019. Retrieved 31 January 2019.
  7. ↑ "Galvani Bioelectronics". FierceBiotech. Retrieved 13 July 2020.
  8. ↑ "Verily Life Sciences". verily.com. Retrieved 15 February 2017.
[edit]